Back to Newsroom

PTC Therapeutics Completes Enrollment of Landmark Trial in Duchenne Muscular Dystrophy

SOUTH PLAINFIELD, NJ – September 9, 2014 – PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that it has completed enrollment of ACT DMD, the Phase 3 confirmatory trial of Translarna™ (ataluren) for patients with nonsense mutation Duchenne muscular dystrophy (nmDMD). Top-line data from the trial is expected in the second half of 2015 and will support further approvals globally, following European approval received earlier this year.

Click here to read more